Li Jie, National People’s Congress: Proposal to increase support for the development of innovative pharmaceutical companies

Li Jie, National People’s Congress: Proposal to increase support for the development of innovative pharmaceutical companies
In 2019, a series of policy measures implemented by the state focused on tax and fee reductions, and gradually increased additional tax reductions and fees by more than 2 trillion yuan. Tax burdens of all industries were reduced to varying degrees, effectively stimulating the vitality of market potential and enhancing confidence in economic development.In 2020, the real economy is still facing the challenges of industrial upgrading and structural transformation, how to further reduce the pressure of corporate funds, so that companies can better invest limited funds in R & D and innovation, cultivate innovation vitality, promote enterprise scale, and sustainable development toImportant.Li Jie, NPC deputy and chairman of Renfu Pharmaceutical. The controversy brought by Li Jie, chairman of Renfu Pharmaceuticals, the representative of enterprises in various countries, at the two sessions this year is about further optimizing taxation policies and encouraging technological innovation of enterprises.Li Jie hopes that the tax rate can be further reduced.He believes that under the current economic environment, tax rate reduction is the most direct means of reducing burdens for enterprises. “I hope that the subsequent tax rate can be three and two levels, and reduce the 13% tax rate applicable to most manufacturing industries.”In addition, Li Jie also proposed to reduce the labor cost of enterprises. He specifically explained:” In 2019, Guobanfa[2019]No. 13 comprehensive plan for reducing social insurance premium rates was announced, which reduced the burden on social insurance premium-paying enterprises to a certain extent.However, on the whole, the labor cost of enterprises is still too high. We hope that the government will continue to reduce the rates of enterprise contributions such as social security, employment security for disabled persons, and trade union budgets.”For companies developing innovative drugs, Li Jie hopes that the government can increase its support.Li Jie said that in 2016, the local drug regulatory agency formally put forward the concept of “innovative drugs” for the first time, defined as “drugs not marketed in China and abroad”, and the scope was changed from “Chinese new” to “global new”.Under the current economic environment, the expansion of traditional pharmaceutical companies is difficult to inherit, and domestic pharmaceutical companies need to innovate and change.Having independent research and development of innovative medicines is the key to sustainable development of enterprises.However, the investment in R & D of innovative drugs is large, long, and has a high failure rate. This requires the support of the state as well as the persistence of enterprises.”We hope that the state can formulate special step-by-step preferential policies for companies developing innovative drugs.Li Jie said.Sauna, Ye Wang editor Yan Ze proofreading Chen Diyan